Frederick R Mackintosh

Suggest Changes
Learn More
BACKGROUND Although currently available 5-hydroxytryptamine type 3 receptor (5-HT3) antagonists are effective, not all patients receiving these agents achieve adequate control of chemotherapy-induced(More)
To develop culture conditions devoid of serum that would support the ex vivo expansion and maintenance of hematopoietic stem cells (HSC) with engraftment capability, we performed in vitro studies in(More)